Form 4: Agios Pharmaceuticals Chief Legal Officer Reports Routine Stock Transactions Following PSU Vesting

Agios Pharmaceuticals' Chief Legal Officer, James William Burns, reported the vesting of 6,000 performance share units and the subsequent sale of 2,799 shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• James William Burns, Chief Legal Officer of Agios Pharmaceuticals, Inc. (AGIO), reported transactions on June 24, 2025.
• He acquired 6,000 shares of common stock through the vesting of performance share units (PSUs). These PSUs were granted on March 1, 2023, and 50% vested upon the achievement of a specified research milestone on June 24, 2025.
• Concurrently, Mr. Burns sold 2,799 shares of common stock at a price of $33.54 per share.
• This sale was executed to cover tax withholding obligations related to the vesting of the performance share units and was conducted under a Rule 10b5-1(c) plan.
• Following these transactions, Mr. Burns directly beneficially owns 28,650 shares of Agios Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there's a sale of shares, it's a routine tax-related transaction following the positive event of performance share unit vesting due to a research milestone achievement. This indicates progress for the company.

Positives

• The vesting of 6,000 performance share units indicates the achievement of a specified research milestone by Agios Pharmaceuticals, which is a positive operational indicator.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent sale.

Negatives

• The sale of 2,799 shares by a Chief Legal Officer, even for tax purposes, slightly reduces insider ownership.

Future Outlook

The document indicates that the remaining 50% of the performance share units will vest upon the achievement of a specified regulatory milestone, suggesting future operational progress is anticipated.

Management Comments

• The filing notes that the transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c), and such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023.

Industry Context

This Form 4 filing reflects a routine insider transaction common in the biotechnology and pharmaceutical industries, where executive compensation often includes performance-based equity awards like PSUs. The vesting of such units, tied to research milestones, is a standard practice that aligns executive incentives with company performance and R&D progress.

Related Party Transactions

• The transaction involves the Chief Legal Officer, James William Burns, acquiring shares through the vesting of performance share units and subsequently selling a portion to cover tax obligations, which is a standard related-party transaction for executive compensation.

Stakeholder Impact

• Shareholders: The vesting of PSUs tied to a research milestone could be seen as positive, indicating progress. The subsequent sale for tax purposes is a routine event and generally not a significant concern.
• Employees: The achievement of a research milestone could boost morale and confidence in the company's R&D pipeline.

Next Steps

• Vested shares will be delivered to the reporting person within three business days after such shares become vested.
• The remaining 50% of the performance share units are contingent on the achievement of a specified regulatory milestone.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Trading, Stock Transaction, Performance Share Units, PSU Vesting, Rule 10b5-1, Chief Legal Officer, James William Burns, Equity Compensation, Tax Withholding